ERBB2 and breast carcinoma: In support of a potential clinical relevance, we also found that low PAK4/high RELB expression was associated with better prognosis in the HER2-positive breast cancer subtype (Supplementary Fig. 5d, e), in which PAK4 expression was the highest (Fig. 1b).